Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Articles with Puma Biotechnology
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Here's Why Puma Biotechnology Tumbled Today | The Motley Fool
Puma Biotechnology
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
Puma Biotechnology, Inc. | LinkedIn
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Can Puma Biotechnology Inc (PBYI) Stock Rise to the Top of Healthcare Sector Tuesday?
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
Puma Biotechnology
What Happened To Puma Biotechnology?
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Former Puma Biotechnology Executive Sentenced to More than Two Years in Prison for Insider Trading | BioSpace
Puma Biotechnology's (PBYI) Lowest Price: $1.6400 (on 05-11-2022)
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
